



Decode Immunity with Antibody Sequencing.

We are empowering life science breakthroughs with next generation protein sequencing. Our technology and services enable biotech and pharmaceutical companies to extract the full potential of antibodies in ways never before possible.



Antibody Sequencing & Discovery Services.

REmAb

Monoclonal antibody sequencing from small protein samples, no need for hybridoma or DNA information. Full sequence in record time..

Explore REmAb

REpAb

Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.

Explore REpAb

MATCHmAb

Antibody verification by real-time peptide mapping. Antibody sequence confirmation service for reproducibility.

Explore MATCHmAb

Other

Ask us about recombinant expression, non-antibody protein sequencing, intact mass, CDRs and PTM analysis services.

Why Protein Sequencing.

At Rapid Novor, we focus on the biggest building blocks of life: proteins. Biological systems are incredibly diverse, constantly changing, and hard to understand without directly accessing the functional, circulating proteins.

Unlock Impossible Antibody Breakthroughs.

Ground breaking software, technology and methods developed through our seamless integration of bioinformatics, mass spectrometry and pioneering research. Antibody sequencing and discovery platforms capable of delivering results where nobody else can.

Speed Up Antibody Discovery.

Use protein sequencing in a high-throughput workflow to get faster answers, focus efforts and identify additional high-quality molecules that cannot be found through other methods. Avoid troubleshooting delays with easy and detailed structural insights, routinely.

Rapid Novor, Inc.

Unit 450, 137 Glasgow St., Kitchener, Ontario, Canada, N2G 4X8

Antibody & Protein Sequencing, Discovery & Proteomics Company

Services for Biologics Drug Discovery.

Eliminate Variability & Optimize Your Lead Candidates.

Monoclonal antibodies are characterized by their vast diversity in both structure and activity. As such, researchers may evaluate hundreds of mAbs while identifying their best binders. But this selection process can take months as conventional techniques for biologics discovery do not include tools that can truly assess mAb biophysical diversity that directly affects specificity and affinity. With next generation protein sequencing (NGPS), mAb leads can be analyzed down to the amino acid level for targeted and controlled development in parallel.

Polyclonal antibodies are well used in drug discovery research because they recognize and bind many different epitopes of a single antigen; however, polyclonal mixtures are difficult to work with due to the lack of information of each antibody in the mixture. pAb sequencing allows direct access to high-affinity antibodies from the native immune response, deriving their amino acid sequences, which can be expressed as a set of mAbs that perform as well or better than the original polyclonal mixture. pAb sequencing is the most direct method for therapeutic antibody discovery.

We support the biologics drug discovery and validation pipeline with direct access to the amino acid sequence of the functional protein.. Contact Us to discover how we can help with your biologics drug discovery application.

de novo mAb Sequencing

Examine fusion products and derive the sequence of important candidates, or extract the CDR sequences to add to your framework or platform for future engineering.

Explore REmAb

Therapeutic mAb Discovery and Development

Exploit the therapeutic potential of circulating pAbs. Access a wide array of biologically relevant CDRs for antibody engineering, or extract exact sequences from the diverse antibody repertoire for recombinant expression.

Explore REpAb + Expression

Research Security

A biologic's amino acid sequence is often integral to its IP. Thanks to Rapid Novor's NGPS, scientists from the top 18 pharma have safeguarded their discoveries by directly accessing the protein sequence of their mAb drugs.

Explore MATCHmAb

Regulatory Approval and ADA

Anti-drug antibody assays are vital to establish clinical safety and efficacy of biologics. REpAb® polyclonal antibody sequencing can capture reliable control reagents that faithfully recapitulate the ADA response.

Explore REpAb

Binding Kinetics

Measure key antibody properties (ie. binding affinity, specificity, kinetics) to screen and identify lead candidates with optimal therapeutic potential.

Explore SPR

Epitope Mapping

Identify linear, conformational, and structural epitopes. Characterize antibody binding sites on target antigens for FDA and EMEA regulatory filings and IP protection.

Explore HDX-MS